drug reps to give out information about UNAPPROVED uses of their prescription drugs

February 1999

The FDA will now allow drug reps to give out information about UNAPPROVED uses of their prescription drugs.

Until now, drug reps could only give info about FDA-approved indications...even if their drug is commonly used "off-label."

That's why you've never seen a rep detail Neurontin for neuropathic pain...Wellbutrin for attention deficit disorder, etc.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

drug reps to give out information about UNAPPROVED uses of their prescription drugs
Lovenox (enoxaparin) is the first low-molecular-weight heparin approved to TREAT deep vein thrombosis (DVT)
new drug for intermittent claudication
Monitoring plasma homocysteine levels is becoming more common
Gastroenterology new guidelines for treating H. pylori
Neurology & Pain new CNS stimulant called Provigil (modafinil)
Diabetes mix Humalog (insulin lispro) with long-acting insulins
Diabetes Glyset (miglitol), a new alpha-glucosidase inhibitor for type 2 diabetes
Diabetes Fenugreek supplements are now being promoted to diabetics
Women's Health more attention focused on urinary incontinence
Women's Health Fosamax (alendronate) causes adverse GI effects more often than we originally thought
Infectious Diseases new drug for HIV, Ziagen (abacavir)
Infectious Diseases minocycline is useful for mild to moderate scleroderma
Infectious Diseases Herp-Eeze, a new herbal supplement promoted for herpes
Multiple Sclerosis EARLIER treatment for patients with multiple sclerosis (MS)
Generics two significant new generics
Vaccines new pediatric immunization schedule
Vaccines revaccinate some patients with pneumococcal vaccine after five years
Practice chart of new drugs approved by the FDA in 1998